---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-023179"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:32:03.324052+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Ocugen Q1 net loss $0.05/share, cash $26.4M; OCU400 Phase 3 underway

## Summary
- Net loss $0.05/share for Q1 2024 vs $0.08 loss in Q1 2023; total operating expenses $13.2M, down 29% YoY.
- Cash and cash equivalents $26.4M at March 31, 2024, versus $39.5M at December 31, 2023.
- OCU400 Phase 3 liMeliGhT trial cleared by FDA; dosing begins Q2 2024; EMA supports MAA submission.
- OCU410 (dAMD) cohort 2 dosing complete; Phase 2 expansion expected Q3 2024. OCU410ST cohort 2 enrollment initiated.
- NeoCart GMP facility renovated; Phase 3 contingent on funding. OCU500 IND planned mid-2024.

## SEC filing metadata
- accession: 0001628280-24-023179
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000162828024023179/0001628280-24-023179-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000162828024023179/ocgn-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-023179
- JSON: https://secwatch.observer/filing/0001628280-24-023179.json
- Plain text: https://secwatch.observer/filing/0001628280-24-023179.txt

## Key facts
- Earnings Releases
  Ocugen, Inc. reported first quarter 2024 results: net income a $0.05 net loss per common share, EPS a $0.05 net loss per common share.
  - Period: first quarter 2024
  - Net income: a $0.05 net loss per common share
  - EPS: a $0.05 net loss per common share
  - Result: reported results
  source text: Ocugen reported a $0.05 net loss per common share for the three months ended March 31, 2024 compared to a $0.08 net loss per common share for the three months ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372299/000162828024023179/0001628280-24-023179-index.htm
- Earnings Releases
  Ocugen, Inc. reported three months ended March 31, 2024 results: net income Total operating expenses for the three months ended March 31, 2024 were $13.2 million, EPS a $0.05 net loss per common share.
  - Period: three months ended March 31, 2024
  - Net income: Total operating expenses for the three months ended March 31, 2024 were $13.2 million
  - EPS: a $0.05 net loss per common share
  - Result: reported results
  source text: Ocugen reported a $0.05 net loss per common share for the three months ended March 31, 2024 compared to a $0.08 net loss per common share for the three months ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372299/000162828024023179/0001628280-24-023179-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.